PRESS RELEASE PRESS RELEASE N° 20 / 2014 of 11/03/2014 MOLOGEN AG: Presentation of DNA vaccine against Press Release | Pressemitteilung | Press Release leishmaniasis at IMED 2014 Berlin, November 3, 2014 – The LEISHDNAVAX consortium, with the biotechnology company MOLOGEN AG as a key partner, presented preclinical data of the leishmaniasis vaccine (MGN1331) in a poster at the International Meeting on Emerging Diseases and Surveillance (IMED) in Vienna. Data on the immunogenicity and prophylactic efficacy of the DNA-based leishmaniasis vaccine was shown. Leishmaniasis is a neglected tropical disease that severely affects large populations worldwide. A vaccine is needed to prevent, control and eliminate leishmaniasis in endemic regions. The abstract and more information on LEISHDNAVAX (MGN1331) can be found on: http://imed.isid.org/. Abstract details: Abstract number: 22.149 Title: "Multiantigen T cell epitope-enriched leishmaniasis vaccine" About leishmaniasis Leishmaniasis is a cluster of diseases caused by different species of Leishmania parasites with diverse clinical manifestations, most of them difficult to treat or even fatal if untreated. On five continents, leishmaniasis occurs in tropical and subtropical regions and has been classified by the WHO as a very important Neglected Tropical Disease. According to WHO (2010), approximately 350 million people are at risk of contracting leishmaniasis with an estimated number of approximately two million new cases per year. Recent epidemiological evaluations by WHO resulted in an estimate of around 40,000 deaths caused by visceral leishmaniasis annually. Among parasitic diseases, this rate is surpassed only by malaria. Moreover, each year approximately 1.2 million people develop cutaneous leishmaniasis. MOLOGEN AG · Fabeckstr. 30 · 14195 Berlin · Germany I PHONE +49-30-841788-0 I FAX +49-30-841788-50 I EMAIL info@mologen.com I www.mologen.com REGISTERED OFFI CE Berlin · Germany I REGISTER OF COMPANIES HRB 65633B · Amtsgericht Berlin-Charlottenburg · Germany I TAX NO. 29 / 407 / 04068 VAT REG. NO. DE 192 609 647 I BANK DETAILS Berliner Sparkasse / LBB AG · BLZ 100 500 00 · ACCOUNT NO. 12 20 01 46 60 · BIC BELADEBEXXX IBAN DE53 1005 0000 1220 0146 60 I EXECUTIVE BOARD Dr. Matthias Schroff (Chairman) · Dr. Alfredo Zurlo · Jörg Petraß CHAIRMA N OF THE SUPERVISORY BOA RD Oliver Krautscheid PRESS RELEASE About MGN1331 The DNA vaccine MGN1331 consists of a combination of MIDGE® vectors encoding different Leishmania antigens. In animal models, promising efficacy and a very good safety profile of Press Release | Pressemitteilung | Press Release MGN1331 has been shown. In the field of biotechnology, transport vehicles for conveying nucleic acids (mostly DNA) are called vectors. The MIDGE® technology developed by MOLOGEN (MIDGE® stands for Minimalistic Immunologically Defined Gene Expression) is also termed a DNA vector. However, unlike other DNA vectors (plasmids, viruses), the MIDGE® vector contains only the information necessary for the actual effect. Its minimalistic design ensures avoidance of undesirable components often found in conventional vectors. MIDGE® vectors form the basis for a broad spectrum of modern, DNA-based applications. These vectors are designed with various characteristics that are partly individualized and are exceptionally well-suited for both gene therapy for cancer and DNA-based vaccination against infectious diseases. Members of the LEISHDNAVAX consortium:  London School of Hygiene & Tropical Medicine (LSHTM)  Charité - Universitätsmedizin Berlin (Charite)  Indian Institute of Chemical Biology (IICB), Kolkata  Institut Pasteur de Tunis (IPT)  Hebrew University of Jerusalem (HUJI)  Rajendra Memorial Research Institute of Medical Sciences (RMRI-MS)  Drugs for Neglected Diseases Initiative (DNDi)  MOLOGEN AG About MOLOGEN AG MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases. The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal -2- PRESS RELEASE randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune Press Release | Pressemitteilung | Press Release therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG. MOLOGEN AG Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 – 86 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forwardlooking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forwardlooking statements and has no obligation to update such statements in order to accurately reflect the current situation. -3-